The ORR was 33% vs 25% in BRAFmut patients with no prior BRAF inhibitor therapy and with a prior BRAF inhibitor.19 Puzanov et al pooled analysis of clinical trials KEYNOTE-001, 002, and 006, in which pembrolizumab served as first-line or salvage therapy for unresectable melanoma. The gene discussed is BRAF; the disease is melanoma.